En español

Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)

This is a 12-week, intent-to-treat, randomized controlled trial to evaluate the impact of N-Acetylcysteine (NAC) versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM) interventions, on cannabis use among treatment-seeking adults.  The primary analysis will evaluate the impact of NAC versus PBO on cannabis use during the 12-week treatment intervention with the primary outcome measure being the proportion of negative urine cannabinoid tests submitted during active treatment, compared between the two treatment groups.

CTN Protocol ID: 
ClinicalTrials.gov ID: 
Principal Investigator(s)
Kevin Gray, M.D.
Associate Professor
Medical University of South Carolina
125 Doughty Street, MSC861
Charleston, SC 29455

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.